SILVER SPRING
National Priority Voucher awarded for Zenocutuzumab
- Sponsor
- Partner Therapeutics, Inc.
- Drug
- Bizengri · zenocutuzumab
- Indication
- NRG1 fusion-positive cholangiocarcinoma
FDA awarded a Commissioner’s National Priority Voucher to Partner Therapeutics for Zenocutuzumab in NRG1 fusion-positive cholangiocarcinoma.
What this means
Bizengri (zenocutuzumab) is a targeted antibody treatment that blocks two proteins, HER2 and HER3, which drive certain cancers. The FDA awarded a National Priority Voucher to Partner Therapeutics for its use in NRG1 fusion-positive bile duct cancer. This voucher could speed up future drug reviews and highlights the need for treatments in this rare cancer type.
Drug Watch — recent news on Bizengri
- Ron Duguay’s daughter gives health update after former Rangers star’s scary fall - nypost.com
- Zenocutuzumab Expands Targeted Treatment Options for NRG1 Fusion-Positive Cholangiocarcinoma - HMP Global Learning Network
- Targeted Therapy Zenocutuzumab Approved for Ultrarare Type of Bile Duct Cancer - American Association for Cancer Research (AACR)
- Arndt Vogel: Zenocutuzumab in Rare NRG1 Fusion-Positive Cholangiocarcinoma - Oncodaily
- Zenocutuzumab Shows Durable Antitumor Activity in NRG1 -Positive Cholangiocarcinoma - The ASCO Post